HUMIK-BETA-1
As of the edition of 20 October 2026, HUMIK-BETA-1 is a drug: went quiet in 2019; acts on IL2RB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2019
- Kind
- Unknown
- Registered trials
- 3, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Digestive system; Immune system; Infections; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL2RB | Interleukin-2 receptor subunit beta | P14784 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| All trials | 3 |